Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab Monotherapy in HER2-Amplified Biliary Tract Cancer
CTR20202607Phase 2Completed
- Sponsor
- BeiGene
- Start
- Jan 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of zanidatamab in biliary cancer, sponsored by BeiGene. Started Jan 2021; status: completed.
02
Drugs
zanidatamab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20202607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202607.